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Abstract
Developmental genes are silenced in embryonic stem cells by a bivalent histone-based chromatin mark. It has been
proposed that this mark also confers a predisposition to aberrant DNA promoter hypermethylation of tumor suppressor
genes (TSGs) in cancer. We report here that silencing of a significant proportion of these TSGs in human embryonic and
adult stem cells is associated with promoter DNA hypermethylation. Our results indicate a role for DNA methylation in the
control of gene expression in human stem cells and suggest that, for genes repressed by promoter hypermethylation in
stem cells in vivo, the aberrant process in cancer could be understood as a defect in establishing an unmethylated promoter
during differentiation, rather than as an anomalous process of de novo hypermethylation.
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Introduction
In the course of embryonic development, cells are initially
totipotent but, after a few divisions, begin to lose potency and are
transformed into pluripotent cells, finally becoming terminally
differentiated somatic cells. The progressive loss of potency during
differentiation has fundamental implications for disease because
recovery of pluripotency through nuclear reprogramming is one of
the major challenges in regenerative medicine [1], and because
disruption of the developmental process that gives rise to a
terminally differentiated somatic cell from its corresponding
progenitor cell may result in malignant transformation [2].
Differentiation of human embryonic stem cells (hESCs) requires
the repression of transcription factors involved in maintaining
pluripotency and the activation of developmental genes. Both
processes are directed by specific epigenetic mechanisms. An
example of the first type is the promoter hypermethylation-
dependent repression of pluripotency-maintaining genes such as
NANOG and OCT4 as stem cells differentiate [3]. So far,
activation of developmental genes during stem cell differentiation
upon DNA methylation has been less thoroughly studied. Instead,
these developmental genes have been reported as being in a
repressed state during early stages of development due to the
establishment of a specific pattern of histone modification, termed
‘‘bivalent domains’’, which consists of large regions of H3 lysine 27
methylation harboring smaller regions of H3 lysine 4 methylation
[4]. This chromatin-repressive status is mediated by the Polycomb
group of proteins [5,6] and is thought to predispose to aberrant
promoter hypermethylation in cancer [7–9]. The finding that
treatment of hESCs with the demethylating drug 59-Aza-29-
deoxycytidine causes cardiac differentiation and gene reactivation
[10] prompted us to consider whether promoter DNA methylation
could contribute to the establishment and maintenance of specific-
gene repression in hESCs. To establish its existence and its
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putative relationship with aberrant promoter hypermethylation in
cancer, we compared the promoter DNA methylation pattern of a
panel of 800 cancer-related genes between hESCs and different
types of terminally differentiated adult tissues and cancer cell lines.
Results
Promoter DNA methylation profiling in hESCs, normal
differentiated tissues and cancer samples
We used Illumina Goldengate Methylation Arrays to compare
the DNA methylation status of 1,505 sequences (from 807 genes)
in eight independently isolated hESCs lines, 21 normal human
primary tissues (NPTs) corresponding to six normal tissue types
(NTTs) and 21 human cancer cell lines (CCLs) (see Methods). The
genes included in the methylation arrays were chosen on the basis
of their importance to cellular behavior and differentiation and
included genes previously reported to be differentially methylated ,
as well as tumor suppressor genes, oncogenes and genes coding for
factors involved in cell cycle check point [11]. We first selected the
autosomal genes (766) from the arrays in order to exclude DNA
methylation-dependent X chromosome inactivated genes. As
previously reported, unsupervised clustering of the samples
exclusively using the methylation signals of the autosomal genes
(1,421 sequences) contained in the arrays enabled the correct
classification of each sample within its corresponding group
(hESC, NPT, or CCL) (Figure 1A, and see Figure S1 in the
online supplementary data for this article), thereby confirming that
each group of samples has a specific DNA methylation signature
[11]. We then attempted to classify the genes in the array in
relation to their methylation status in the three types of sample
analyzed (hESC, CCL, and NPT) (Figure 1A, and Tables 1 and
S1). We found that 65.31% (928/1,421) of the sequences were not
frequently hypermethylated in hESCs (array signal#0.7 in$25%
(2/8) of the samples) and that half of them (464/928) were
frequently hypermethylated in CCLs (array signal.0.7 in$25%
(6/21) of the samples). The vast majority of these sequences
(99.78%, 463/464) were unmethylated in at least one of the NTTs
analyzed (array signal,0.3 in$1/6 NTTs). This finding is
consistent with the view that genes aberrantly hypermethylated
in cancer (i.e., not hypermethylated in normal tissues) are not
hypermethylated in hESCs [8]. We called this group of genes
classical Class A cancer hypermethylated genes (Tables 1 and
S1).
Significantly, we found that 34.69% (493/1,421) of the
sequences were frequently hypermethylated in hESCs (array
signal.0.7 in$25% (2/8) of the samples). Most of these
(79.72%, 393/493) were also frequently hypermethylated in CCLs
(array signal.0.7 in$25% (6/21)) of the samples). Again, many of
them (32.32%, 127/393) were unmethylated in at least one of the
NTTs analyzed (array signal,0.3 in$17% (1/6) NTTs)
(Figure 1, and Tables 1 and S1). In contrast to the Class A
cancer hypermethylated genes, those of this group were also
frequently hypermethylated in hESCs, so we propose that they can
be considered members of a different category of cancer
methylated genes, which we have termed Class B cancer
hypermethylated genes. Of the 697 sequences frequently hyper-
methylated in cancer and unmethylated in at least one of the
NTTs analyzed, 444 (66.70%) and 127 (18.22%) were respectively
classified as Class A and Class B genes (Figure 1, and Tables 1
and S1), which indicates, contrary to expectation, that a
substantial proportion (around 20%) of cancer methylated genes
are also frequently hypermethylated in hESCs.
Intriguingly, not all the genes frequently hypermethylated in
CCLs were completely unmethylated in all the NTTs analyzed
(Figure 1, and Tables 1 and S1). The frequency of
hypermethylation in normal tissues is only of moderate importance
for the Class A classical cancer methylated genes, as most of them
(78.83%; 350/444 sequences) are unmethylated in NPTs. On the
other hand, only 20 sequences corresponding to Class B genes
were unmethylated in all the NTTs analyzed (Table 1). When a
gene is methylated in some but not all normal tissues, the
methylation is probably involved in the specification of a tissue
type during development [12]. When the gene is not hypermethy-
lated in hESCs, tissue-type-dependent selective methylation must
Figure 1. DNA methylation profiling in human embryonic stem cells (hESCs), normal primary tissues, and cancer cell lines. (A)
Methylation profiles of Class A-I (350), A-II (94), B-I (20), and B-II (107) genes in hESCs (8), normal (21), and cancer (21) samples obtained by Illumina
arrays. The methylation levels vary from fully methylated (red) to fully unmethylated (white). The right-hand columns show the methylation status of
histone H3 and Polycomb occupancy of the same genes obtained from previously published data [5,12,16]. Blue, methylation at K4 and K27; orange,
methylation at K4 alone; green, no methylation at K4 or K27; black, presence of the Polycomb protein SUZ12. (B) Enrichment of the Polycomb protein
SUZ12, the bivalent chromatin signature (K4/K27) or the absence of both marks (none) in Class A and Class B genes (upper panel) and Class I and
Class II genes (lower panel).
doi:10.1371/journal.pone.0003294.g001
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occur. In contrast, when the gene is frequently hypermethylated in
hESCs, it most probably becomes selectively demethylated upon
differentiation as an epigenetic mechanism that is able to facilitate
tissue specification. Conversely, when a gene is unmethylated in all
normal differentiated cells and hypermethylated in stem cells, the
loss of promoter methylation that necessarily occurs during
differentiation is more likely to be involved in early differentiation
processes than in tissue specification [12]. Thus, we defined two
new subcategories for both Class A and B cancer methylated
genes: Subcategory I, for genes that are always unmethylated in
normal tissues, and subcategory II, for genes that are sometimes
methylated in normal tissues (Figure 1, and Tables 1 and S1).
The percentage of Class A-II and Class B-II genes is quite similar
(7.53% and 6.61%) (Table 1). However, the percentage of genes
in Class A-I (24.63%) is much higher than that in Class B-I
(1.41%). The genes in these four categories (A-I, A-II, B-I, and B-
II) represent 58.2% of all the sequences present in the methylation
arrays. By considering the methylation status of the three groups of
Table 1. Classification of genes according to their promoter methylation status in hESCs, normal tissues, and CCLs, and proposed
biological role for each group.
Methylation in
hESCs
Methylation
in CCLs Methylation in NTTs Proposed biological role
Name
of the
category
Group of
genes from
Supplementary
Table 1
1421
Sequences
Hypermethylated
in hESCs.0.7
in$2/8 samples
Hypermethylated in
hCCLs.0.7 in$6/21
samples
159 Sequences (11.19%)
hypermethylated in all
NTTs (.0.7 in 6/6 samples)
Genes constitutively hypermethylated - G1
20 Sequences (1.41%)
unmethylated in all NTTs
(,0.3 in 6/6 samples)
Genes that become demethylated early
during hESC differentiation or that become
aberrantly hypermethylated during in vitro
culture hESCs. Their hypermethylation might
provide advantages to the cancer cells.
Class B-I G2
393 Sequences
(27.66%)
107 Sequences (7.53%)
sometimes unmethylated
(#0.3 signal in $1/6 and
#5/6 samples)
Genes which demethylation during hESC
differentiation might be important for
lineage specification. Their hypermethylation
might provide advantages to the cancer cells.
Class B-II G3
493 Sequences
(34.69%)
Not hypermethylated
in hCCLs
16 Sequences (1.13%)
hypermethylated in all
NTTs (.0.7 in 6/6 samples)
Genes that become frequently demethylated
in cancer
- G4
Not.0.7 in$6/21
samples
11 Sequences (0.77%)
unmethylated in all
NTTs (,0.3 in 6/6
samples )
Genes that become demethylated early
during hESC differentiation. Their
hypermethylation might not provide
advantages to the cancer cells.
- G5
100 Sequences
(7.04%)
39 Sequences (5.07%)
sometimes unmethylated
(#0.3 signal in $1/6 and
#5/6 samples)
Genes which demethylation during hESC
differentiation might be important for
lineage specification. Their hypermethylation
might not provide advantages to the cancer
cells.
- G6
Not
hypermethylated
in hESCs not.0.7
in$2/8 samples
Hypermethylated in
hCCLs.0.7 in$6/21
samples
1 Sequences (0.07%)
hypermethylated in all
NTTs (.0.7 in 6/6
samples)
Genes hypermethylated early during hESC
differentiation. Their hypermethylation
should not provide advantages to the
cancer cells.
- G7
350 Sequences (24.63%)
unmethylated in all NTTs
(,0.3 in 6/6 samples)
Genes constitutively unmethylated during
normal development. Their aberrant
hypermethylation provide advantages to
the cancer cells.
Class A-I G8
464 Sequences
(32.65%)
94 Sequences (6.61%)
sometimes unmethylated
(#0.3 signal in $1/6 and
#5/6 samples)
Genes which hypermethylation during hESC
differentiation might be important for
lineage specification. Their aberrant
hypermethylation provide advantages to
the cancer cells.
Class A-II G9
928 Sequences
(65.31%)
Not hypermethylated
in hCCLs
1 Sequences (0.07%)
hypermethylated in all
NTTs (.0.7 in 6/6
samples)
Genes hypermethylated early during hESC
differentiation. These genes could be
aberrantly hypomethylated in cancer.
- G10
Not.0.7 in$6/21
samples
404 Sequences (28.43%)
unmethylated in all NTTs
(,0.3 in 6/6 samples)
Genes constitutively hypomethylated - G11
464 Sequences
(32.65%)
52 Sequences (3.66%)
sometimes unmethylated
(#0.3 signal in $1/6 and
#5/6 samples)
Genes which hypermethylation during hESC
differentiation might be important for lineage
specification. These genes could be aberrantly
hypomethylated in cancer.
- G12
The classification criteria are described in the Methods section.
doi:10.1371/journal.pone.0003294.t001
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samples (hESCs, NPTs, and CCLs) we were able to cluster most of
the remaining genes in the array into eight additional categories
(Table 1), which included, for example, two categories of genes
that we define as being constitutively methylated (methylated in
hESCs, CCLs, and all NTTs; 11.19%) or constitutively unmethy-
lated (unmethylated in hESCs, CCLs, and all NTTs; 28.43%)
genes, respectively. We therefore propose that DNA methylation is
not important for the regulation of the genes in these categories.
The classification of genes according to their methylation status in
hESCs, CCLs, and NTTs, and the interpretation of the biological
role of DNA methylation in the genes in each group is summarized
in Table 1. Table S1 lists the genes in each group.
It is important to note here that all the previously described
percentages refer to the 807 genes included in methylation arrays,
whereas the overall percentage of genes in each group might be
different if the entire genome were considered. The classification
threshold that we employed to identify genes frequently hyper-
methylated in hESCs (more than 70% of promoter CpG
methylation in more than 25% of samples analyzed) is that which
is commonly used to define a gene as being frequently
hypermethylated in cancer [13]. To assess whether our observa-
tions hold true for astringent classification thresholds we
reexamined our data in search of: i) sequences hypermethylated
in most of the hESCs analyzed (array signal.0.7 in$75% (6/8) of
the hESCs) and, ii) sequences ‘‘fully methylated’’ in some of the
hESCs analyzed (array signal.0.8) in$25% (2/8) of the hESCs)
(Table S2). We found that 5 B-I and 84 B-II sequences fitted the
first criterion, and 13 B-I and 86 B-II sequences fitted the second
(Table S2), which indicates that our conclusions remain valid
even with these stricter classification thresholds.
It has recently been shown that prolonged in vitro culture of
hESCs is associated with DNA methylation instability [14,15]. To
assess whether promoter hypermethylation of our Class B genes is
associated with the in vitro culture process, we compared our data
with those previously published by Bibikova et al. [11]. These
authors used the Goldengate methylation platform to compare the
methylation status of the 1505 CpG sites contained in the arrays in
ten hESC lines at low and high passages. They found that,
although methylation changes did occur with passage number,
such changes were small compared with the differences among cell
types. They found five genes (ASCL2, GALR1, MEST, NPY, and
SLC5A8) to be consistently hypermethylated with the passage
number (increase in methylation level.0.34 in at least two cell
lines (20%)). Three of those genes (ASCL2, NPY, and SLC5A8) are
members of Class B-I but, interestingly, none was a Class B-II
gene. These results suggest that prolonged in vitro culture was only
responsible for the promoter hypermethylation of a small fraction
(3/97, 3%) of our Class B genes, and that the effect appeared to be
greater in Class B-I genes.
As previously stated, it has recently been proposed that
developmental genes are silenced in embryonic stem cells by a
Polycomb-dependent bivalent histone-based chromatin mark
[4,5], which is thought to predispose to aberrant DNA promoter
hypermethylation of TSGs in cancer [7–9]. As we found that a
subset of cancer methylated genes can also be methylated in
hESCs we wanted to investigate the relationship between
promoter hypermethylation and the Polycomb-dependent histone
modification pattern in hESCs. To this end, we compared our
methylation data for the Class A-I, A-II, B-I, and B-II genes with
the previously reported histone modification profile and Polycomb
occupancy of the same genes in embryonic stem cells [5,12,16]
(Figure 1 and Table S3). Consistent with a previous report [9],
we found that around 35% of the sequences frequently
hypermethylated in cancer and unmethylated in at least one of
the NTTs analyzed contained chromatin-repressive marks at their
promoters (228-277/697 harbored meK27, and 236/697 con-
tained SUZ12). Intriguingly, comparing our methylation data with
those of Mikkelsen et al. [16] we observed that the vast majority
(96.4%) of genes harboring meK27 also contained meK4 and that
only around 30% of the genes frequently hypermethylated in
cancer presented the bivalent chromatin domain (meK4/meK27)
in hESCs (Table S3).
When we compared the chromatin patterns and Polycomb
occupancy in the Class A-I, A-II, B-I, and B-II genes we found
each group to have a specific chromatin signature (p,0.00001).
Class A genes were more enriched in Polycomb and bivalent
marks (47.5% and 45.5–57.3% of genes, respectively) than Class B
genes (19.7% and 21.4–32.7%, respectively) (p,0.00001)
(Figure 1B and Table S4). The enrichment of the bivalent
mark in Class A genes is primarily due to the low levels of this
chromatin signature in Class B-II genes (Table S4). Indeed, Class
B-I genes exhibit similar levels of meK4/meK27 to Class A genes
(Table S4) (p,0.00001). Interestingly, the Class II genes, were
much less frequently occupied by Polycomb proteins and exhibited
fewer bivalent marks (33.3% and 26.5–38.8% of genes, respec-
tively) (p,0.00001) than did Class I genes (45.7% and 47.6–
59.3%, respectively), (Figure 1B and Table S4). The lower levels
of the bivalent mark in Class II genes were primarily due to the
low levels of this chromatin signature in Class B-II genes (Table
S4). Indeed, Class A-II genes had similar levels of meK4/meK27
to those of Class I genes (Table S4) (p,0.00001).
TSGs repressed by promoter hypermethylation in hESCs
To test the hypotheses formulated on the basis of the data
obtained from the methylation arrays, we focused our attention on
four Class B genes (frequently hypermethylated in cancer and
hESCs) that were previously widely reported to be genes with
tumor suppressor properties and that are frequently hypermethy-
lated in cancer. We selected two (MGMT and SLC5A8) [17,18]
from the Class B-I subcategory (unmethylated in all NTTs) and
two (PYCARD and RUNX3) [19,20] from Class B-II (unmethy-
lated in a number of NTTs). We first employed bisulfite
sequencing of multiple clones to determine accurately the
promoter DNA methylation status of these genes in hESCs and
normal tissues (Figure 2A, and Figures S2, S3, S4, S5). In all
cases, bisulfite sequencing data corroborated the results obtained
from the arrays and showed that the hypermethylation observed in
hESCs affected the majority of the CpGs surrounding the
transcriptional start-site of the selected genes. MGMT and
SLC5A8 (Class B-I) presented dense promoter hypermethylation
in hESCs but not in normal differentiated tissues (Figure 2A, and
Figures S2, S3) whilst Class B-II genes were frequently
hypermethylated in hESCs and sometimes in normal tissues
(Figures S4, S5). To understand better the role in promoter
hypermethylation of our selected TSGs in hESCs and NTTs, we
used q-RT-PCR to measure their expression in both sample
groups (Figure 2B, and Figures S2, S3, S4, S5). We found that
promoter hypermethylation was always associated with gene
repression, but its absence in somatic primary tissues did not
necessarily involve the upregulation of the gene. For example,
whilst SLC5A8 was hypomethylated in all the normal tissues
analyzed (Figure S3A,B), it was only overexpressed in brain,
liver, and colon (Figure S3C).
Loss of promoter hypermethylation and gene activation
during in vitro differentiation of hESCs
To demonstrate further that the differentiation of hESCs is
associated with less DNA methylation at the promoter region of
DNA Methylation
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certain genes, we induced the in vitro differentiation of the hESC
line Shef-1 in two cell lineages (fibroblast-like cells and neural
precursors) (Figure 3A). We assessed the lineage specification
using previously published markers [21] (Figure 3A, right-hand
panels) and then used methylation arrays to identify genes that
became hypomethylated during differentiation. We found that
12.98% (37/285) of the genes hypermethylated in Shef-1 (which
were not methylated in all the NTTs analyzed) become
unmethylated during in vitro differentiation. Of these, 12 genes
become unmethylated during neuron differentiation and 25
during spontaneous differentiation (Table S5). Three of these
genes were common to both groups (Figure 3B) and two of them
belonged to Class B-II. It is of particular note that, whilst 9/25 of
the genes unmethylated during spontaneous differentiation were of
Class B-II, none of the 12 genes unmethylated during neuron
differentiation belonged to this category.
To demonstrate that some TSGs that are frequently hyper-
methylated in cancer and hESCs can lose methylation during
differentiation, we focused our attention on DLC1. We chose this
gene because the methylation arrays had shown that it lost
promoter methylation during spontaneous differentiation of Shef-
1, and because it is known to be a TSG that is frequently
hypermethylated in cancer (Figure S6) [22,23]. Bisulfite sequenc-
ing of multiple clones corroborated the results obtained with the
methylation arrays and showed that DLC1 promoter is hyper-
methylated in Shef-1 and becomes unmethylated during sponta-
neous, but not neural, differentiation (Figure 3C). In q-RT-PCR
experiments DLC1 was poorly expressed in the Shef-1 cell line
and became overexpressed during spontaneous, but not neural,
differentiation (Figure 3D).
TSGs repressed by promoter hypermethylation in
hematopoietic stem cell progenitors
Having demonstrated that some cancer genes are hypermethy-
lated and repressed in hESCs and that they can lose methylation
during in vitro differentiation of hESCs, we investigated whether this
phenomenon is restricted to embryonic development or, conversely,
is an epigenetic mechanism associated with stemness status
regardless of the ontogenetic stage of the cell. We used methylation
arrays to identify genes hypermethylated in CD34+ somatic stem
cell progenitors (Figure S7) compared with peripheral blood
lymphocytes and neutrophils, two types of adult primary cells
derived from the CD34+ hematopoietic progenitors. We identified
362 significantly hypermethylated sequences in the CD34+ cells
(array signal.0.7) (Table S6). The vast majority of these sequences
(92.27%, 334/362) were also methylated in hESCs and most were
frequently hypermethylated in CCLs (83.43%, 302/362)
(Figure 4A, and Table S6). These results suggest that the
hypermethylation of cancer genes can occur in stem cells regardless
of the ontogenetic stage (embryo vs. adult). We next identified nine
sequences that were significantly hypermethylated in CD34+ cells
relative to peripheral lymphocytes, and 16 sequences that were
hypermethylated in these progenitor cells relative to neutrophils
(Table S7). Most of the sequences identified were also frequently
hypermethylated in hESCs (8/9 for lymphocytes and 14/16 for
neutrophils) and CCLs (6/9 for lymphocytes and 13/16 for
neutrophils). In addition, there were no sequences common to
lymphocytes and neutrophils and most of them were sometimes
hypermethylated in NPTs. Interestingly, 28 of these sequences were
previously classified as Class B-II genes whilst none of them was
from Class B-I (Figure 4A).
Finally, to demonstrate that some cancer methylated genes are
also frequently methylated in somatic progenitor stem cells and
that their methylation is important for lineage specification, we
considered two genes: RUNX3 and AIM2. We selected RUNX3
because, in agreement with previously published data [24], our
methylation arrays showed that, relative to CD34+ cells, RUNX3
was hypomethylated in peripheral lymphocytes but not in
peripheral neutrophils. AIM2 was selected because it was
previously thought to be a TSG that is frequently hypermethylated
in cancer (Figure S8) [25] and because, unlike RUNX3, it
becomes unmethylated specifically in the myeloid lineage
(Figure 4B,C). The bisulfite sequencing data confirmed the
results obtained with the arrays, showing that the CD34+ cells and
the peripheral lymphocytes were densely methylated at the
promoter of AIM2 gene whilst the peripheral neutrophils were
almost unmethylated (Figure 4B). To determine the role of
Figure 2. Promoter DNA hypermethylation and repression of MGMT in hESCs. (A) Bisulfite genomic sequencing of multiple clones of the
MGMT promoter in hESCs (I3, H14), normal primary tissues (Pool lymphocytes, normal breast) and two CCLs of lymphoid and breast origin (U937 and
MDA-MB-231, respectively). Black, methylated CpG; white, unmethylated CpG; red, CpG not present. The green bar above the diagram of the MGMT
CpG island indicates the location of the probe used in the methylation arrays. (B) Relationship between MGMT promoter hypermethylation and
expression in hESC, normal, and cancer samples. The upper panel shows the relative methylation signal obtained with the methylation arrays and the
lower panel the expression levels of MGMT mRNA relative to GAPDH.
doi:10.1371/journal.pone.0003294.g002
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promoter hypermethylation of AIM2 and RUNX3 in hematopoi-
etic differentiation, we used q-RT-PCR to analyze their expression
in our groups of samples (Figure 4C). We found that promoter
hypermethylation was always associated with gene repression in
both genes and that loss of promoter methylation in AIM2 and
RUNX3 in peripheral lymphocytes and neutrophils, respectively,
was associated with their reexpression (Figure 4C).
Discussion
Aberrant promoter hypermethylation of TSGs and differenti-
ation factors is a central epigenetic alteration in cancer [26,27].
The genes undergoing such alterations in cancer have been
reported to be repressed in hESCs by the establishment of
‘‘bivalent chromatin domains’’ consisting of activating (H3 lysine
27 methylation) and repressing (H3 lysine 4 methylation) histone
marks that keep them poised for activation but, at the same time,
predisposes them to aberrant promoter hypermethylation in adult
cancers [7–9]. Herein we demonstrate that another level of
complexity exists whereby some of the genes frequently aberrantly
hypermethylated in cancer are also frequently hypermethylated in
hESCs. Our results suggest that, as was previously proposed for
mouse cells [28], promoter DNA methylation can be an important
factor in gene regulation in hESCs.
On the basis of the methylation status in hESCs we established
two categories of cancer methylated genes: Class A genes, which
are frequently unmethylated in hESCs, and Class B genes, which
are frequently hypermethylated in hESCs. As we unexpectedly
found that a substantial proportion of the genes included in both
groups were also frequently hypermethylated in normal differen-
tiated tissues, we established two new subcategories of cancer
methylated genes: subcategory I, for genes that are mostly
unmethylated in normal tissues, and subcategory II, for genes
that are sometimes hypermethylated in normal tissues. The
biological interpretation of aberrant methylation within Classes
A and B cancer methylated genes and their two subcategories is
completely different. Class A-I genes are frequently hypermethy-
lated in cancer but not in normal tissues or hESCs. These genes
Figure 3. Loss of promoter DNA methylation during in vitro differentiation of hESCs. (A) Left-hand images, Shef-1 stem cell line (upper)
and the same cells after neural differentiation (middle) and spontaneous differentiation to fibroblast-like cells (lower). The right-hand panels show the
relative mRNA levels of pluripotency (NANOG, OCT4), neuroectodermal (PAX6, NEUROD1), and mesodermal (COL1A1, FN1) markers before and after
Shef-1 differentiation. (B) Number of sequences hypomethylated during Shef-1 neural (red circle) and spontaneous (blue circle) differentiation, and
their overlap with Class B-I and Class B-II genes (black circles). (C) Bisulfite genomic sequencing of multiple clones of the DLC1 promoter in Shef-1
stem cell line (upper) and the same cells after neural differentiation (middle) and spontaneous differentiation to fibroblast-like cells (lower). The color
code is as for Figure 2. (D) Relationship between DLC1 promoter hypermethylation and expression during differentiation of Shef-1 cells. The upper
panel shows the relative methylation signal obtained with the methylation arrays and the lower panel the expression levels of DLC1 mRNA relative to
GAPDH.
doi:10.1371/journal.pone.0003294.g003
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are not supposed to be regulated by DNA methylation during
normal development and thus the hypermethylation in cancer
should always be interpreted as an aberrant process. Class A-II
genes are frequently methylated in CCLs and sometimes in
normal tissues, but rarely in hESCs. Methylation of these genes
may be important for lineage specification and should be
considered aberrant in cancer when it occurs in a tumor type in
whose corresponding normal tissue it is not hypermethylated.
Class B-I genes (excluding ASCL2, NPY, and SLC5A8 genes, whose
promoter DNA hypermethylation in hESC lines could be due to
the in vitro culture process [11]) are frequently hypermethylated in
hESCs and cancer cells lines but never in normal tissues, which
suggests that the loss of methylation at the promoters of these
genes might be an important influence on the loss of pluripotency
during development. Their hypermethylation in cancer should
always be considered as aberrant. Class B-II genes are frequently
hypermethylated in hESCs and cancer cells, but, as they are also
sometimes methylated in normal tissues, their hypermethylation in
cancer may only be considered aberrant in tumor types in whose
normal counterparts they are completely unmethylated. Apart
from this, the fact that not all the genes frequently hypermethy-
lated in cancer were completely unmethylated in all the normal
tissues analyzed is a highly important finding in cancer epigenetics
[26] because the promoter hypermethylation of a gene in a
particular tumor type should not be considered aberrant when the
promoter of this gene is equally hypermethylated in its non-
tumorigenic counterpart.
We found the percentage of Class A-II and Class B-II genes to
be quite similar (7.53% and 6.61%), which suggests that the
probability of aberrant hypermethylation or improper loss of
methylation is similar in genes in which hypermethylation or loss
of methylation, respectively, is necessary for lineage specification.
However, the percentage of genes in Class A-I is much higher than
that in Class B-I (24.63% and 1.41%), implying that it is much
easier for a gene that is not naturally regulated by DNA
methylation to become aberrantly hypermethylated than for there
to be loss of methylation of developmental genes during hESC
differentiation.
Comparing our DNA methylation data with those previously
published on the histone modification profile and Polycomb
occupancy of the same genes in embryonic stem cells [5,12,16] we
found that the vast majority of genes harboring meK27 also
contained meK4. This concurs with the observation that most of
the genes repressed in stem cells by Polycomb-repressive marks
also contain histone-active marks [4]. However, as only around
one-third of the genes frequently hypermethylated in cancer
presented the bivalent chromatin domain (meK4/meK27) in
hESCs, our results suggest that this chromatin signature in cancer
methylated genes could be less abundant in hESCs than previously
expected. However, we must recognize that our study is limited to
Figure 4. Cancer genes hypermethylated in somatic stem cells. (A) The left-hand panel shows the numbers of sequences that are
hypermethylated in the somatic stem cells CD34+, and hypermethylated in hESCs and CCLs. Note that most of the sequences hypermethylated in
somatic stem cells are also hypermethylated in embryonic stem cells. The right-hand panel shows the number of sequences hypermethylated in
CD34+ cells (black circle) classified as Class B-II genes (red circle). Sequences hypermethylated in CD34+ cells were never classified as Class B-I genes
(blue circle). (B) Bisulfite genomic sequencing of multiple clones of the AIM2 promoter in Shef-1 and I3 stem cell lines (upper), CD34+ hematopoietic
stem cell progenitors (middle), and terminally differentiated hematopoietic cells (peripheral lymphocytes and neutrophils). The color code is as for
Figure 2. (C) Relationship between AIM2 and RUNX3 promoter hypermethylation and expression in CD34+ somatic hematopoietic stem cell
progenitors and terminally differentiated hematopoietic cells (peripheral lymphocytes and neutrophils). The upper panel shows the relative
methylation signal obtained with the methylation arrays and the lower panel the expression levels of AIM2 and RUNX3 mRNAs relative to GAPDH.
doi:10.1371/journal.pone.0003294.g004
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the set of 807 genes selected for inclusion in the methylation
arrays, and that the overall pattern needs to be determined in
genome-wide DNA methylation studies, to establish how general
our observations are.
Within our four categories of genes we found those of Class A to
be more enriched in Polycomb and bivalent marks than Class B
genes, which suggests that the previously described scenario
involving bivalent chromatin domains and Polycomb occupancy
of cancer methylated genes in embryonic stem cells [7–9] could be
more frequent in Class A than in Class B genes. Interestingly, the
Class II genes, which we previously suggested were involved in
lineage specification because their promoter methylation was tissue-
dependent, were much less frequently occupied by Polycomb
proteins and exhibited fewer bivalent marks than did Class I genes,
which we previously believed to be involved in early differentiation
processes. The lower levels of the bivalent mark in Class II genes
were primarily due to the low levels of this chromatin signature in
Class B-II genes, implying that this subcategory of genes might be
relevant to lineage specification. Zhao et al. [12] proposed that genes
harboring meK4/meK27 bivalent marks were primarily involved in
early differentiation, whilst those without either mark were involved
in lineage specification. As we observed that Class I genes were
enriched in the bivalent mark and Class B-II genes were frequently
depleted of both marks, the data of Zhao et al. [12] support our
hypothesis that Class I genes are primarily involved in early
differentiation processes whilst Class B-II (excluding those whose
promoter DNA hypermethylation depends on prolonged in vitro
culture) are more associated with lineage specification. This
hypothesis is further supported by the fact that the gene ontology
classification of the two categories shows that Class I genes are
associated with biological processes involved in early differentiation,
whilst most Class B-II genes are associated with those linked to
lineage specification (Table S8).
To investigate further the role of promoter DNA methylation of
genes aberrantly hypermethylated in cancer in hESCs, we
compared the DNA methylation and expression status of four of
the genes identified in the methylation arrays (MGMT and
SLC5A8 [17,18] from Class B-I, and PYCARD and RUNX3
[19,20] from Class B-II). We found that promoter hypermethylation
was always associated with gene repression, but its absence in
somatic primary tissues did not necessarily involve the upregulation
of the gene, as was the case for SLC5A8, in which there was no
overexpression upon loss of promoter methylation in peripheral
lymphocytes. In view of this, we hypothesized that promoter
hypermethylation of the Class B cancer methylated genes in hESCs
(excluding those whose promoter DNA hypermethylation depends
on prolonged in vitro culture [11]) can be a natural process employed
by stem cells to ensure the silencing of genes whose expression is
associated with stemness status. When stem cells differentiate, these
genes may lose their promoter hypermethylation, which could allow
the genes to become overexpressed. However, this does not imply
that the gene has become immediately activated, as demonstrated
by the fact that some of these genes were still repressed in
differentiated tissues. The loss of promoter methylation during
differentiation could merely keep these genes poised for activation
until they are later required by the somatic cells. The lack of
hypomethylation-associated activation in some mature tissues
suggests that signals other than the lack of methylation are necessary
for these genes to be activated.
By forcing the in vitro differentiation of the hESC line Shef-1 we
identified 12 and 25 genes that become unmethylated respectively
during neuron and spontaneous differentiation. Interestingly, three
of these genes were common to both groups, suggesting that they
may be involved in early differentiation processes. This implication
is supported by the fact that two of the genes were from Class B-I,
which we previously proposed were involved in early development.
Whilst the majority of genes unmethylated during spontaneous
differentiation were of Class B-II, none of the genes unmethylated
during neuron differentiation belonged to this category. This may
largely be explained by the fact that the ten genes that were
unmethylated during neuron differentiation and did not belong to
Class I or II were not classified as ‘‘unmethylated in at least one
normal tissue type analyzed’’ because their intermediate levels of
methylation in normal tissues did not allowed their classification
into any of the four categories described. Moreover, there were
many more hypomethylated genes (relative to Shef-1) in normal
brain than in neural Shef-1-derived cells. The observations suggest
two things: i) the in vitro differentiation of hESCs does not reproduce
all the epigenetic features present during in vivo differentiation, and
ii), the unguided spontaneous differentiation of our hESC achieves
more epigenetic hits in vivo than does neural differentiation.
One of the genes that we identified using this approach is
DLC1,. a TSG frequently inactivated by promoter hypermethyla-
tion in cancer cells [22,23]. We found that DLC1 becomes
unmethylated and overexpressed specifically during spontaneous,
but not neural, differentiation of the Shef-1 cell line, which
suggests that loss of DNA methylation-dependent expression of
this gene might be involved in lineage specification. This is
supported by the essential role of DLC1 during embryonic
development, whereby DLC1-deficient mice are unviable [29].
Finally, we wondered whether the methylation-dependent
repression of cancer genes in hESCs is a molecular process
associated with embryonic development or if, by contrast, it is an
epigenetic mechanism involved in the maintenance of stemness
status. The fact that the CD34+ somatic stem cell progenitors
featured numerous genes frequently hypermethylated in cancer
that are repressed by promoter hypermethylation suggests that, at
least for these genes, the process could be associated with stemness
status regardless of the ontogenetic stage of the cell, rather than
being an event restricted to embryonic development. Since
CD34+ cells are primary non-cultured cells, we can also discount
the possibility that in vitro culture of the hESCs is largely
responsible for hypermethylation, which accords with previously
published findings [11,30,31].
By comparing the DNA methylation status of CD34+
progenitor cells with those of two types of primary cells that are
terminally differentiated from the former (peripheral blood
lymphocytes and neutrophils) we identified several genes that lost
methylation specifically in just one of lineages. This, in conjunction
with knowledge that most of the sequences identified were
sometimes hypermethylated in NPTs and most were previously
classified as Class B-II genes (those whose regulation by
methylation is important for lineage specification and that present
aberrant methylation in cancer), suggests that the genes hyper-
methylated in CD34+ progenitor cells that become unmethylated
during differentiation are those primarily involved in lineage
specification. That none of the sequences identified in the CD34+
progenitor cells was from Class B-I may well be because the
CD34+ cells are not the primary hematopoietic progenitor cells
and because Class B-I genes lose methylation in the transition
from earlier progenitor stem cells to CD34+ cells. This explanation
is consistent with the putative role of these genes in early
development [12] but needs further investigation. Moreover, from
our point of view, the fact that some cancer methylated genes are
also frequently hypermethylated in adult stem cells is particularly
important to our understanding of aberrant methylation in cancer.
In the context of the hypothesis of the stem cell origin of cancer
[32,33], our results suggest that, for TSGs hypermethylated in
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stem cells in vivo, the aberrant process in cancer could be
understood as a defect in establishing an unmethylated promoter
during differentiation, rather than as an anomalous process of de
novo hypermethylation (Figure 5).
Using the above approach, we identified two genes, AIM2 and
RUNX3, that were hypermethylated and repressed in CD34+
hematopoietic progenitor cells and that became unmethylated and
overexpressed in myeloid and lymphoid lineages, respectively. Both
genes are aberrantly hypermethylated in cancer [20,25], which
indicates that genes frequently hypermethylated in cancer can be
naturally repressed by promoter methylation not only in hESCs but
also in somatic stem cells. Moreover, the lineage-specific loss of
methylation and upregulation of the two genes suggests that their
expression might be important in lineage specification during
hematopoietic differentiation and, more importantly, that the
process can be regulated by DNA methylation. RUNX3 is a well-
known transcription factor that regulates lineage-specific gene
expression in developmental processes [34]. Our observation that
RUNX3 loses methylation and becomes expressed during lymphoid,
but not myeloid, development is consistent with previous studies
showing the necessity of RUNX3 for T cell development during
thymopoiesis [35,36], and that RUNX3 knockout mice have T cell
phenotypes [20,37]. Finally, considering all the available evidence
and following similar reasoning to before, the aberrant hyper-
methylation of RUNX3 observed in the lymphoid human CCL Raji
should be understood as the failure of CD34+ cells to lose the
promoter methylation necessary to reactivate the gene during
hematopoietic differentiation.
The results presented here are important for four reasons: i) we
unexpectedly found a subset of cancer methylated genes that are
also frequently methylated in hESCs; ii) the pattern of expression of
these genes implies that DNAmethylation might have an important
role in the control of their expression in hESCs; iii) determining
DNA methylation status in hESCs allowed us to define two
categories of cancer methylated genes: Class A, containing genes
that are never hypermethylated in hESCs, and Class B, containing
genes that are frequently hypermethylated in hESCs; and, probably
most important, iv) the hypermethylation of some Class B genes in
adult stem cells in vivo suggests that, for this group of genes, the
aberrant methylation in cancer can be understood as a defect in
establishing an unmethylated promoter during differentiation,
rather than as an anomalous process of de novo hypermethylation.
Materials and Methods
Stem cell lines
Cell pellets and/or DNA/RNA were obtained from the
following laboratories: Shef-1 (Servicio de Inmunologia, HUCA,
Oviedo, Spain), Shef-4, Shef-5, Shef-7, H7, H14 (CSCB,
University of Sheffield, Sheffield, UK), H181 (CABIMER, Seville,
Spain), I3 (Institute of Reconstructive Neurobiology, University of
Bonn, Germany), and cultured and passaged following established
protocols by each laboratory. The laboratories that were involved
in the establishment and maintenance of these cell lines are
members of the European project ESTOOLS (LSHG-CT-2006-
018739). The laboratories participating in ESTOOLS only use
embryonic stem cell lines derived from IVF embryos that will not
be transferred into the womb. These embryos were donated for
research according to the legal requirements of the country of
origin. All donors gave their written informed consent. Profiling
epigenetic regulation in hESCs is one of the research objectives of
the ESTOOLS research program, which is supervised by the
ethics advisory panel of the ESTOOLS project. The cell lines were
established from different embryos and were maintained under
different conditions, thereby ensuring the independence of our
results for type of line and culture conditions. In vitro differentiation
of the Shef-1 cell line was achieved as previously described [38].
Primary CD34+ hematopoietic somatic stem cells were purified
from cord blood (CB) samples obtained from healthy newborns
upon progenitor’s informed consent. CB harvesting procedures
and informed consents were approved by the Local Hospital
Ethics Board. Mononuclear cells were isolated using Ficoll-
Hypaque (Amersham Biosciences, Baie d’Urfe´, Quebec, Ontario,
Canada). CD34+ cells were purified by positive selection using
anti-CD34 microbeads (Miltenyi Biotech, Madrid, Spain). Im-
munomagnetic CD34+ cell-containing cell suspensions were
passed through Pro-MACS immunomagnetic columns (Miltenyi
Biotech). The flow-through contained the purified CD34+
fraction. The purity was 80% 6 12% (n= 2) (Figure S7), as
measured by flow cytometry (FACSCanto, Becton Dickinson, Palo
Alto, CA) using a fluorochrome-conjugated anti-CD34 antibody
(BD).
Cancer cell lines and primary tissues
MDA-MB-231, Hela, CasKi, SiHa, HCC1937, BT-474, LoVo,
HCT115, DLD1, Co115, HT29, SW48, HCT116, RKO, U937,
HL60, AKATA, Raji, Ramos, Karpas, and Farage (ATCC) cell
lines were maintained in DMEM medium supplemented with
10% FBS and grown at 37uC under 5% CO2.
Lymphocytes and neutrophils were separated from peripheral
blood of healthy volunteers, by centrifugation, using HistopaqueH-
1077 (SIGMA). Lymphocyte-enriched fractions were obtained by
collecting the upper pillow of mononuclear cells and granulocytes
(mainly neutrophils) following hemolysis of the remaining pellet.
RNA from breast, liver, heart, muscle, lung, colon, and lymph
node samples were obtained from Ambion (Austin, TX). DNA
from breast, heart, brain, and muscle was obtained from Biochain
(Hayward, CA). The subjects who participated in this study gave
written consent to being subjected to the procedures.
DNA methylation profiling using bead arrays
Methylation was assessed at 1,505 CpG sites using Illumina
Goldengate Methylation Arrays, as described in Bibikova et al.
[11]. The amount of bisulfite-modified target DNA that hybridizes
to each spot of the Illumina chip was quantified and standardized
over a range from 0.0 to 1.0 (effectively 0% and 100% likelihood
of gene promoter hypermethylation, respectively). In this work, all
Figure 5. Proposed model of aberrant methylation in cancer
for genes frequently hypermethylated in stem cells in vivo. The
loss of promoter hypermethylation might be necessary for overexpres-
sion of a subset of Class B genes during differentiation. The aberrant
process in cancer for these genes should be understood as a defect in
establishing an unmethylated promoter during differentiation, rather
than as an anomalous process of de novo hypermethylation.
doi:10.1371/journal.pone.0003294.g005
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sequences with at least 70% likelihood of being hypermethylated
(hybridization signal$0.7) were considered hypermethylated for
each specific sample, whereas sequences whose equivalent signal
was below 30% (hybridization signal,0.3) were considered
unhypermethylated.
To identify gene promoters that could be hypermethylated in a
significant number of samples of a particular group (human
embryonic stem cells, normal tissue types, and CCLs), we selected
all sequences whose hybridization signal was $0.7 in at least 25%
of the samples of each group. In general, sequences were classified
by the following stepwise algorithm: First, sequences were
classified according to the percentage of hESCs hypermethylated
in each specific probe set. Therefore, sequences that were
hypermethylated in $25% and ,25% of samples were considered
to hypermethylated and unhypermethylated, respectively. Se-
quences were then tested for hypermethylation in hCCLs and
classified according to the percentage ($25% or ,25%) of
hypermethylated samples in each probe set. Finally, the percent-
ages of normal tissue types that were hypermethylated in each
probe set were calculated, and sequences were classified as
hypermethylated in all normal tissue types (100% of samples with
signal $0.7), unmethylated in all normal tissue types (100% of
samples with signal ,0.3) or unmethylated in some of the samples
but not in all samples (signal,0.3 in at least one, but not all,
samples). This algorithm allowed most sequences in the array to be
assigned to one of the 12 groups described in Table 1.
We next determined whether any of the groups was significantly
enriched in a specific type of histone modification. For this reason,
all sequences were classified according to publicly available data
on histone-modification and Polycomb occupancy [5,12,16]. A
chi-square test was performed to identify significant differences in
frequencies between the groups of sequences. Up to 27 tests were
conducted so Bonferroni-adjusted, two-tailed probabilities of
,0.0018 (0.05/27) were considered significant.
Bisulfite sequencing of multiple clones
DNA methylation was determined by PCR analysis after
bisulfite modification of the DNA. Bisulfite genomic sequencing
was carried out as previously described [39]. A minimum of six
colonies of each sequence and sample were automatically
sequenced to determine their degree of methylation. Bisulfite
genomic-sequencing primers were designed using Methyl Primer
Express SoftwareH (Applied Biosystems). Primer sequences are
shown in Table S9.
RNA purification and real-time RT-PCR analysis
RNA was isolated with TRIzol Reagent (Invitrogen) according
to the manufacturer’s instructions. For RT-PCR, 1 mg of total
RNA was reverse-transcribed using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems). Quantitative real-
time RT-PCR was performed using TaqManH Gene Expression
Assays and the ABI PRISMH 7900 sequence-detection system
(Applied Biosystems). Data are expressed as means 6 SD of three
replicates of each experiment.
Supporting Information
Figure S1 Unsupervised cluster analysis of human embryonic
stem cells (hESCs), human cancer cell lines (CCLs), and normal
primary tissues based on correlation of methylation profiles of
1,421 sequences. The methylation levels vary from fully
methylated (red) to fully unmethylated (white) sequences. The
final two rows correspond to in vitro-methylated DNA (IVD), used
as a positive control for methylation.
Found at: doi:10.1371/journal.pone.0003294.s001 (0.20 MB
PDF)
Figure S2 Methylation status of MGMT in hESCs, normal
tissues, and CCLs. (A) Methylation profiles of MGMT gene
obtained by Illumina arrays and expressed as relative methylation
from fully unmethylated (0) to fully methylated (1). (B) Bisulfite
genomic sequencing of multiple clones of the MGMT promoter in
hESCs and normal primary tissues. Color code as for Fig. 1. (C)
Relative expression of MGMT in hESCs and normal tissue. qPCR
data are normalized with respect to GAPDH expression and
presented as the percentage relative to normal lymphocytes.
Found at: doi:10.1371/journal.pone.0003294.s002 (0.04 MB
PDF)
Figure S3 Hypermethylation of SLC5A8 in hESCs. (A)
Methylation profiles of SLC5A8 gene obtained by Illumina arrays
and expressed as relative methylation, from fully unmethylated (0)
to fully methylated (1). (B) Bisulfite genomic sequencing of multiple
clones of the SLC5A8 promoter in hESCs and normal primary
tissues. Color code as for Fig. 1. (C) Relative expression of
SLC5A8 in hESCs and normal tissue. qPCR data are normalized
with respect to GAPDH expression and are presented as the
percentage relative to normal lymphocytes.
Found at: doi:10.1371/journal.pone.0003294.s003 (0.03 MB
PDF)
Figure S4 Hypermethylation of PYCARD in hESCs. (A)
Methylation profiles of PYCARD gene obtained by Illumina
arrays and expressed as relative methylation from fully unmethy-
lated (0) to fully methylated (1). (B) Bisulfite genomic sequencing of
multiple clones of the PYCARD promoter in hESCs and normal
primary tissues. Color code as for Fig. 1. (C) Relative expression of
PYCARD in hESCs and normal tissue. qPCR data are
normalized with respect to GAPDH expression and are presented
as the percentage relative to normal lymphocytes.
Found at: doi:10.1371/journal.pone.0003294.s004 (0.03 MB
PDF)
Figure S5 Hypermethylation of RUNX3 in hESCs. (A)
Methylation profiles of RUNX3 gene obtained by Illumina arrays
and expressed as relative methylation from fully unmethylated (0)
to fully methylated (1). Red arrow indicates methylation levels in
normal lymphocytes purified from blood. (B) Bisulfite genomic
sequencing of multiple clones of the RUNX3 promoter in hESCs
and normal primary tissues. Color code as for Fig. 1. (C) Relative
expression of RUNX3 in hESCs and normal tissue. qPCR data
are normalized with respect to GAPDH expression and are
presented as the percentage relative to normal lymphocytes.
Found at: doi:10.1371/journal.pone.0003294.s005 (0.02 MB
PDF)
Figure S6 Hypermethylation of DLC1 in hESCs. Methylation
profiles of DLC1 gene obtained by Illumina arrays and expressed
as relative methylation, from fully unmethylated (0) to fully
methylated (1).
Found at: doi:10.1371/journal.pone.0003294.s006 (0.02 MB
PDF)
Figure S7 Flow cytometry analysis of the purity of CD34+ cells
after purification by positive selection using anti-CD34 microbe-
ads. Detection signals were obtained using a fluorochrome-
conjugated anti-CD34 antibody (BD). Purity was 80% 6 12%
(n= 2).
Found at: doi:10.1371/journal.pone.0003294.s007 (0.01 MB
PDF)
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Figure S8 Hypermethylation of AIM2 in hESCs. Methylation
profiles of AIM2 gene obtained by Illumina arrays and expressed
as relative methylation, from fully unmethylated (0) to fully
methylated (1).
Found at: doi:10.1371/journal.pone.0003294.s008 (0.02 MB
PDF)
Table S1 List of genes belonging to each group defined in
Supplementary Table 1.
Found at: doi:10.1371/journal.pone.0003294.s009 (1.20 MB
XLS)
Table S2 List of genes identified as being hypermethylated in
hESCs using different classification thresholds than that used in
Table S1.
Found at: doi:10.1371/journal.pone.0003294.s010 (0.32 MB
XLS)
Table S3 Methylation data, histone marks, and Polycomb
occupancy for genes in the four main categories: A-I, A-II, B-I,
and B-II. Raw data from the methylation array for each sample
are included. The final three columns summarize information
about histone marks and Polycomb occupation published
elsewhere. In the HK4/K27 methylation column, K4 stands for
3me-lysine 4 of histone H3, while K27 stands for 3me-lysine 27 of
histone H3. In the Polycomb occupation column (+) and (2)
respectively refer to the presence and absence of the protein
SUZ12.
Found at: doi:10.1371/journal.pone.0003294.s011 (0.89 MB
XLS)
Table S4 Histone marks and Polycomb occupation in Class A-I,
A-II, B-I, and B-II genes. The first table shows each group
separately, the second shows Group A vs. group B, and the third
Class I vs. Class II genes. The number of genes is presented with
the probability of each modification on the right and the
percentage on the left.
Found at: doi:10.1371/journal.pone.0003294.s012 (0.04 MB
XLS)
Table S5 List of genes that are hypomethylated during in vitro
differentiation of the embryonic stem cell line Shef-1. Methylation
levels from the Illumina array are reported.
Found at: doi:10.1371/journal.pone.0003294.s013 (0.02 MB
XLS)
Table S6 Genes that are hypermethylated in CD34+ hemato-
poietic stem cell progenitors. Methylation levels from the Illumina
array are reported.
Found at: doi:10.1371/journal.pone.0003294.s014 (0.39 MB
XLS)
Table S7 Genes that are hypomethylated in peripheral blood
lymphocytes and neutrophils relative to CD34+ hematopoietic
stem cell progenitors.
Found at: doi:10.1371/journal.pone.0003294.s015 (0.02 MB
XLS)
Table S8 Summary of the gene ontology GO terms associated
with the genes of Classes A-I, A-II, B-I, and B-II. The analysis was
done using the web tool of the PANTHER database. Corre-
sponding probabilities of each term and the chromatin-associated
gene function (right), based on Zhao et al. (2007), are presented.
Found at: doi:10.1371/journal.pone.0003294.s016 (0.02 MB
XLS)
Table S9 Primers used for bisulfite sequencing.
Found at: doi:10.1371/journal.pone.0003294.s017 (0.02 MB
XLS)
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